AbCellera today announced that LY-CoV555, the lead antibody from the collaboration between AbCellera and Eli Lilly, has entered into human testing for the potential treatment…
AbCellera has raised another round of financing, this time a US $105 million Series B round. The financing was led by OrbiMed and current investor…
AbCellera has entered into a multi-year agreement with Eli Lilly on the discovery of antibodies for up to nine Lilly-selected therapeutic targets. Under the strategic…
This morning the Government of Canada announced $175.6 million in new funding for Vancouver's AbCellera to discover solutions for COVID-19 and build a manufacturing facility…
The BC Tech Association took to Zoom today to announce the finalists for the 2020 Technology Impact Awards (TIAs). BC Tech President and CEO Jill…
AbCellera has received a big financial boost from the Canadian government in its fight against COVID-19. Prime Minister Justin Trudeau announced that the Vancouver-based biotech…
AbCellera and Eli Lilly have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the…
Vancouver's AbCellera has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search…
Exploring your career options in Vancouver? We've got the event for you! Produced in partnership with Techcouver, the Tech Talent Vancouver Job Fair is a…
The time between the coronavirus outbreak capturing our attention and AbCellera working on a solution was impressively short. AbCellera, a biotechnology startup based in Vancouver, discovers…